Zotarolimus

佐他莫司

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameZotarolimus
Drug Alias NameZotarolimusum唑罗莫司唑他莫司咗他莫司佐罗莫司 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMammalian target of Rapamycin (mTORC1) inhibitorsmTOR Complex 2 inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsArteriosclerosisCoronary RestenosisCoronary Artery Disease +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPortugal +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedtronic Vascular IncAbbott Medical Devices
Active IndicationsCoronary Restenosis
Inactive IndicationsArteriosclerosisCoronary Artery DiseaseCoronary Disease +[5] 

Other Information

ATC CodeL04AA
Related LinksWikipediaKEGG